Maravai LifeSciences Holdings, Inc. (MRVI)

NASDAQ: MRVI · IEX Real-Time Price · USD
8.69
+0.11 (1.22%)
Mar 28, 2024, 2:06 PM EDT - Market open

Company Description

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide.

The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.

It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).

This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology.

The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services.

This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services.

The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies.

The company was incorporated in 2020 and is headquartered in San Diego, California.

Maravai LifeSciences Holdings, Inc.
Maravai LifeSciences Holdings logo
Country United States
IPO Date Nov 20, 2020
Industry Biotechnology
Sector Healthcare
Employees 650
CEO William E. Martin III

Contact Details

Address:
10770 Wateridge Circle Suite 200
San Diego, California 92121
United States
Phone (858) 546-0004
Website maravai.com

Stock Details

Ticker Symbol MRVI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $27.00
CIK Code 0001823239
CUSIP Number 56600D107
ISIN Number US56600D1072
SIC Code 2834

Key Executives

Name Position
Carl W. Hull Co-Founder and Executive Chairman
William E. Martin III Chief Executive Officer
Kevin M. Herde Executive Vice President and Chief Financial Officer
Dr. Peter Michael Leddy Ph.D. Executive Vice President and Chief Administrative Officer
Christine Dolan Executive Vice President of Biologics Safety Testing
Debra Hart Senior Director of Investor Relations
Kurt Oreshack Executive Vice President, General Counsel and Secretary
Becky Buzzeo Executive Vice President and Chief Commercial Officer
Dr. Kate E. Broderick Ph.D. Chief Innovation Officer
Christopher Benoit Executive Vice President of Enzymes

Latest SEC Filings

Date Type Title
Feb 29, 2024 10-K Annual Report
Feb 28, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 22, 2024 8-K Current Report
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 8, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 5, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 8, 2023 10-Q Quarterly Report
Nov 7, 2023 8-K Current Report